Last updated: July 15, 2026
DELFLEX (Dextrose 4.25%) W/ Dextrose 4.25% in Plastic Container Suppliers: Who Manufactures and Supplies the Dialysate?
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER is a peritoneal dialysis (PD) solution. The supplier landscape is dominated by the original marketing authorizations and contract manufacturing within the PD supply chain (polyethylene/polypropylene plastic container systems, multi-layer tubing, and dialysate compounding lines).
Supply (marketing/authorization) channel: the key “supplier” for procurement is the marketing authorization holder and the labeled manufacturer for each country’s version of DELFLEX.
Clinical/operational procurement channel: distributors and specialty wholesalers source stock from the marketing authorization holder’s distribution system and contract importers for the local market.
Because supplier identity is jurisdiction- and pack-size dependent (and may change by labeling language, container type, and importer), a complete supplier list cannot be produced from the information provided.
Who supplies DELFLEX with dextrose 4.25% in plastic container in the US?
Answer: No complete, country-specific supplier list can be generated from the provided drug name alone.
What counts as a supplier for PD solutions (procurement definitions)
- Marketing authorization holder (MAH) / brand owner for the labeled DELFLEX product
- Labeled manufacturer (site) on the package insert/label
- Importer (where applicable)
- Authorized distributors and specialty wholesalers supplying to hospitals and clinics
What is the Orange Book status of DELFLEX (dextrose 4.25% PD solution)?
Answer: No Orange Book listing can be determined from the provided product name.
Why Orange Book lookups may not map cleanly
Peritoneal dialysis solutions are often:
- device-adjacent or combination products depending on jurisdiction,
- not covered by FDA’s “drug product” exclusivity in the same way as small molecules,
- marketed under NDA references or without an Orange Book footprint that matches a label-level query.
Which companies manufacture DELFLEX dialysate solutions (4.25% dextrose) under contract?
Answer: A contract-manufacturing roster cannot be produced from the provided input.
Manufacturing bottlenecks that drive supplier concentration
- Sterile solution filling lines and environmental control
- Container manufacturing and bag sealing validation
- Multi-layer plastic compatibility qualification (dextrose, electrolytes, pH adjusters)
How many suppliers exist for DELFLEX 4.25% dextrose in plastic containers?
Answer: The number of active suppliers cannot be determined without jurisdiction-specific label or submission data.
When does supplier exclusivity end for DELFLEX dialysate products?
Answer: Exclusivity timelines are not determinable from the provided information.
What “exclusivity” typically means for compounding/solutions
- Regulatory exclusivity tied to a reference application, not generic-style patent terms
- Possible data exclusivity under specific FDA/BLA/NDA pathways, depending on product category and filing history
What patent estate protects DELFLEX (dextrose 4.25%) and how does that affect sourcing?
Answer: No patent-protection map can be created from the provided information.
Why patent analysis requires a specific product identifier
A patent estate for PD dialysate solutions depends on:
- the exact labeled formulation,
- electrolytes and concentrations beyond dextrose 4.25%,
- container type and packaging claims,
- method-of-manufacture claims.
Which generic or interchangeable PD solutions compete with DELFLEX 4.25% dextrose?
Answer: Competitive supplier alternatives cannot be listed from the provided input.
What to compare in PD dialysate substitution
- Dextrose strength and osmolarity
- Electrolyte composition (Na, Ca, Mg, Cl, lactate/bicarbonate system)
- Container and administration system compatibility (Y-set, tubing system)
What formulation and container patents can restrict supply of DELFLEX 4.25%?
Answer: No formulation/container patent set can be determined without the product’s complete composition and jurisdiction.
Container-adjacent IP categories
- Bag materials and sealing methods
- Leachables/extractables and stability claims
- Shelf-life and packaging validation methodologies
What FDA manufacturing and distribution constraints limit alternative sourcing for DELFLEX?
Answer: FDA GMP and distribution eligibility cannot be tied to named suppliers without jurisdiction-specific manufacturer identification.
Constraint categories
- Site-specific FDA inspections and warning letters
- Supply chain cold-chain requirements (if any) and container integrity validation
- Restricted distribution programs for PD solutions (if applicable by market)
What does the supplier map look like globally for DELFLEX 4.25% dextrose in plastic containers?
Answer: A global supplier map cannot be produced from the provided input.
Jurisdiction-driven variation
- EU member state marketing authorization labeling
- Local importers and distributors
- Packaging configurations and translators of label/SmPC
Key Takeaways
- “DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER” is a product label that is not enough to reliably identify named suppliers without the jurisdiction-specific package labeling or regulatory dossier identifiers.
- Supplier identity for PD solutions is typically the labeled manufacturer and importer in the target country, plus the authorized wholesalers/distributors.
- Patent and exclusivity analyses are not actionable without the exact reference product identifiers and jurisdiction.
FAQs
- What are the typical suppliers for peritoneal dialysis dialysate solutions in hospital procurement?
- How do I identify the labeled manufacturer of DELFLEX 4.25% dextrose from packaging?
- Are DELFLEX PD solutions considered “interchangeable” with other 4.25% dextrose dialysates?
- Do container types (plastic bag vs alternative systems) change regulatory supplier eligibility?
- How should distributors validate GMP and batch traceability for PD dialysate deliveries?
References
(No sources were cited because supplier and regulatory status could not be determined from the provided information.)
